Lastly, to broaden the relevance of our findings, we assessed two additional EGFR-mutant NSCLC cell lines with acquired osimertinib resistance, PC9-OsiR and H1975-OsiR (Supplementary Fig. 12f, g). Here, EGFR is linked to non-small cell lung carcinoma.